Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

MeReC Extra 37

The National Prescribing Centre (NPC) has published MeReC Extra 37 (PDF).

This MeReC discusses recent concerns regarding the cardiovascular safety of anticholinergics in chronic obstructive pulmonary disease (COPD). These concerns were raised in a recent meta-analysis however the data are not conclusive and more work is required. The article recommends discussing the risks and benefits of treatment with patients and provides numerical data for heart attacks in comparison to reductions in exacerbations and hospital admissions.

This publication also discusses recent research that indicated a lack of benefit for aspirin in primary prevention of cardiovascular events in patients with diabetes. The study in question was too small to definitively rule out a benefit for aspirin however it is still important to manage cardiovascular risk factors in people with diabetes mellitus including smoking cessation, blood pressure management and treatment with a statin.

Action: Clinicians who see patients with COPD or diabetes will find this information useful and informative.

Share 'MeReC Extra 37' on Email Share 'MeReC Extra 37' on Delicious Share 'MeReC Extra 37' on Digg Share 'MeReC Extra 37' on Facebook Share 'MeReC Extra 37' on Google+ Share 'MeReC Extra 37' on reddit Share 'MeReC Extra 37' on StumbleUpon Share 'MeReC Extra 37' on Twitter

atomic-wealth

No Comments to “MeReC Extra 37”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,523 spam comments.

atomic-wealth
fond-illness
summer